Table 4.

Antigenic diversity among glioblastoma subset

Number of cases; % of cases with mRNA overexpression
ProneuralMesenchymalClassicalNeural
Glioma antigen/genen = 141n = 160n = 147n = 96
EGFR/EGFR32; 2354; 34118; 8052; 54
Her2/ERBB24; 325; 1635; 247; 7
Survivin/BIRC543; 3222; 146; 419; 20
Nucleolin/NCL30; 2122; 1423; 162; 2
Epha2/EPHA22; 127; 1728; 194; 4
Telomerase/TERT6; 414; 918; 125; 4
B-cyclin/CCNB134; 2420; 137; 512; 13
Sart-1/SART135; 259; 618; 122; 2
Sart-2/DSE2; 157; 362; 13; 3
Sart-3/SART318; 1319; 1220; 143; 3
Aim-2/AIM232; 2338; 245; 310; 10
Trp-1/TYRP113; 923; 148; 515; 16
Tyrosinase/TYR11; 815; 97; 511; 11
GnT-V/MGAT55; 48; 55; 31; 1
GP100/PMEL7; 518; 117; 56; 6
Mart-1/MLANA11; 824; 1511; 710; 10
Mage-1/MAGEA10000
Gage-1/GAGE10000

NOTE: Red denotes preferential statistically significant enrichment (P < 0.05) of mRNA expression in the comparison of the mesenchymal vs. proneural subset.